Trevi Therapeutics, Inc. (TRVI) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-03-17

How it makes money

It earns nothing yet because it is a clinical-stage biopharmaceutical company with no approved products or commercial sales.

The company relies entirely on external capital to fund operations as it develops its sole investigational drug candidate, Haduvio, for chronic cough conditions. It has incurred significant annual net losses since inception, totaling $42.8 million and $47.9 million for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of $329.8 million as of December 31, 2025.

Future earnings depend entirely on successfully completing clinical trials, obtaining regulatory marketing approvals, and commercializing Haduvio or any future product candidates for conditions such as idiopathic pulmonary fibrosis and non-IPF interstitial lung disease.

What protects it: the moat

It protects its future position through patents and proprietary development of Haduvio, though management acknowledges it must continually build and defend its intellectual property portfolio.

As a clinical-stage enterprise, the company relies on its research and development efforts around the kappa receptor agonist and mu receptor antagonist mechanism of Haduvio to secure exclusivity.

Management states that maintaining and protecting its intellectual property portfolio is an ongoing requirement for sustaining any future competitive advantage once products reach the market.

What growth costs

It reinvests heavily in research and development, specifically funding clinical trials, regulatory submissions, and manufacturing scale-up to advance its drug candidates.

Operating expenses are driven by clinical development programs including the planned Phase 3 trials for idiopathic pulmonary fibrosis and Phase 2b trials for non-IPF interstitial lung disease and refractory chronic cough.

Additional capital is required to prepare new drug applications for regulatory agencies, build commercial infrastructure, and manufacture larger quantities of Haduvio for clinical and potential commercial use.

About Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Other companies in Biotechnology